Investors Face August Deadline in GeneDx Securities Fraud Case

The lawsuit, filed by the Rosen Law Firm, contends that GeneDx executives repeatedly misrepresented the impact of the Fabric acquisition on the company’s core business. While the firm publicly claimed the integration would reduce costs and optimize algorithms, the complaint alleges that leadership knew of—or recklessly disregarded—significant problems with Fabric’s viability. These omissions, according to the filing, obscured the true financial health of the combined operations and caused investor losses when the reality surfaced.

Those who purchased shares during the specified window may be eligible to participate in the litigation without incurring out-of-pocket costs through a contingency fee arrangement. While a class has not yet been certified, investors retain the right to select their own counsel or remain absent class members. Serving as a lead plaintiff is not a requirement for participating in potential future recoveries, though the court-mandated deadline of August 3 remains firm for those seeking to represent the class.